ClinicalTrials.gg
CompletedNCT00744367Updated Aug 5, 2016

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

A Phase 3 interventional study of metformin and pioglitazone in Diabetes Mellitus Type 2, sponsored by Hoffmann-La Roche. Completed at 113 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-08-05.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
326
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
63rd of 287
326 · median 100
Started
2008
with 23 others
Phase 3
72 of 293
1 open now
Registered
68th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 63rd largest by enrollment of the 287 interventional ones that give a count, is one of 24 that started in 2008, is one of 72 in phase 3, and was the 68th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This 3 arm study will assess the efficacy of taspoglutide on glycemic control (as assessed by HbA1c) in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone, compared to placebo after 24 weeks of treatment. Patients will be randomized to one of 3 treatment arms: taspoglutide 10mg once weekly, taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) or placebo, in addition to their continued stable metformin plus pioglitazone treatment. After the first 24 weeks patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide 20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

03

Conditions studied

  • Diabetes Mellitus Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, 18-75 years age;
  • type 2 diabetes receiving pioglitazone (>= 30 mg/day) and metformin (>= 1500 mg/day) for at least 12 weeks prior to screening;
  • >=7.0% and \<=10.0% at screening;
  • >= 25 (>23 for Asians) and \<=45 kg/m2 at screening;
  • stable weight +/-5% for at least 12 weeks prior to screening.

Exclusion criteria

Exclusion Criteria:

  • history of type 1 diabetes mellitus or acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma in the previous 6 months;
  • evidence of diabetic complications;
  • clinically symptomatic gastrointestinal disease;
  • myocardial infarction, coronary artery bypass surgery, post-transplantation cardiomyopathy or stroke within the previous 6 months;
  • known hemoglobinopathy or chronic anemia.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
326 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo in addition to continued stable metformin plus pioglitazone treatment. After the first 24 weeks patients on placebo will be switched to taspoglutide 10mg once weekly or taspoglutide 20mg once weekly (after 4 weeks of taspoglutide 10mg once weekly.

    Drug: metformin · Drug: pioglitazone · Drug: placebo · Drug: taspoglutide

  • Experimental
    Taspoglutide 10mg

    Taspoglutide 10mg once weekly in addition to continued stable metformin plus pioglitazone treatment

    Drug: metformin · Drug: pioglitazone · Drug: taspoglutide

  • Experimental
    Taspoglutide 10mg/20mg

    Taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued stable metformin plus pioglitazone treatment.

    Drug: metformin · Drug: pioglitazone · Drug: taspoglutide

Interventions

  • \>1500 mg/day or maximum tolerated dose (MTD)

  • \>= 30 mg/day

  • Drugplacebo

    sc once weekly

  • 10 mg sc once weekly;

  • 20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in HbA1c

    Time frame: 24 weeks

Secondary outcomes

  1. Change from baseline in fasting plasma glucose; change from baseline in body weight; responder rates for HbA1c (target <=7.0%, <=6.5%); responder rates for body weight; beta cell function.

    Time frame: 24 weeks

  2. Safety: adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies.

    Time frame: Throughout the study

07

Study locations

113 sites
  • Birmingham, Alabama 35209, United States
  • Birmingham, Alabama 35294, United States
  • Huntsville, Alabama 35801, United States
  • Muscle Shoals, Alabama 35661, United States
  • Phoenix, Arizona 85028, United States
  • Phoenix, Arizona 85032, United States
  • Buena Park, California 90620, United States
  • Lancaster, California 93534, United States
  • Loma Linda, California 92354, United States
  • Rancho Cucamonga, California 91730, United States
  • Roseville, California 95661, United States
  • San Diego, California 92161, United States
  • Walnut Creek, California 94598, United States
  • Wheatridge, Colorado 80033, United States
  • Hamden, Connecticut 06518, United States
  • Washington, District of Columbia 20017, United States
  • Bradenton, Florida 34208, United States
  • Chiefland, Florida 32626, United States
  • Fort Myers, Florida 33907, United States
  • Gainesville, Florida 32607, United States
  • Hollywood, Florida 33021, United States
  • Miami, Florida 33136, United States
  • New Port Richey, Florida 34652, United States
  • Ocala, Florida 34474, United States
  • Plantation, Florida 33317, United States
  • Tampa, Florida 33614, United States
  • Nampa, Idaho 83687, United States
  • Aurora, Illinois 60504, United States
  • Libertyville, Illinois 60048, United States
  • Evansville, Indiana 47714, United States
  • Des Moines, Iowa 50314, United States
  • Topeka, Kansas 66614, United States
  • Lexington, Kentucky 40504, United States
  • Madisonville, Kentucky 42431, United States
  • New Orleans, Louisiana 70121, United States
  • Frederick, Maryland 21702, United States
  • Oxon Hill, Maryland 20745, United States
  • Detroit, Michigan 48202, United States
  • Ferndale, Michigan 48220, United States
  • Kalamazoo, Michigan 49048, United States
  • Biloxi, Mississippi 39531, United States
  • Olive Branch, Mississippi 38654, United States
  • St Peters, Missouri 63376, United States
  • Omaha, Nebraska 68114, United States
  • Omaha, Nebraska 68131, United States
  • Las Vegas, Nevada 89148, United States
  • Albany, New York 12206-1098, United States
  • Brooklyn, New York 11218, United States
  • Hudson, New York 12534, United States
  • Lake Success, New York 11042, United States
  • Staten Island, New York 10301, United States
  • Charlotte, North Carolina 28262, United States
  • Charlotte, North Carolina 28277, United States
  • Mooresville, North Carolina 28117, United States
  • Wilmington, North Carolina 28401, United States
  • Bismarck, North Dakota 58501, United States
  • Athens, Ohio 45701, United States
  • Cincinnati, Ohio 45219, United States
  • Kettering, Ohio 45429, United States
  • Norman, Oklahoma 73071, United States
  • Medford, Oregon 97504, United States
  • Beaver, Pennsylvania 15009, United States
  • Bensalem, Pennsylvania 19020, United States
  • Carlisle, Pennsylvania 17015, United States
  • Levittown, Pennsylvania 19056, United States
  • Melrose Park, Pennsylvania 19027, United States
  • Pittsburgh, Pennsylvania 15236, United States
  • Cranston, Rhode Island 02920, United States
  • Greer, South Carolina 29651, United States
  • Bellaire, Texas 77401, United States
  • Dallas, Texas 75230, United States
  • Dallas, Texas 75231, United States
  • Houston, Texas 77030, United States
  • San Antonio, Texas 78205, United States
  • Salt Lake City, Utah 84102, United States
  • Federal Way, Washington 98003, United States
  • Brasilia, 70390-155, Brazil
  • Forlateza, 60430-350, Brazil
  • Fortaleza, 60120-021, Brazil
  • Fortaleza, 60155-290, Brazil
  • Fortaleza, 60430-370, Brazil
  • Mogi Das Cruzes - Sp, 08780-090, Brazil
  • Passo Fundo, 99010-901, Brazil
  • Porto Alegre, 90035-001, Brazil
  • Recife, 50100-130, Brazil
  • Sao Paulo, 01221-020, Brazil
  • Sao Paulo, 01244-030, Brazil
  • Sao Paulo, 04022-001, Brazil
  • Sao Paulo, 05403-000, Brazil
  • Mount Pearl, Newfoundland and Labrador A1N 1W7, Canada
  • Hamilton, Ontario L8N 3Z5, Canada
  • London, Ontario N6A 5R8, Canada
  • Toronto, Ontario M9W 4L6, Canada
  • Montreal, Quebec H2W 1T8, Canada
  • Pointe-claire, Quebec H9R 4S3, Canada
  • San Jose, 755-1000, Costa Rica
  • Bondy, 93143, France
  • Dijon, 21079, France
  • Nantes, 44093, France
  • Narbonne, 11108, France

Showing the first 100 of 113 sites across 9 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2008
First posted
Sep 1, 2008
Start
Oct 2008
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results delay requested
Jul 26, 2016
Last update
Aug 5, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00744367
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 1, 2008
Start date
Oct 2008
Primary completion
Nov 2010
Completion
Nov 2010
Last update
Aug 5, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Metformin · Pioglitazone · Taspoglutide

Start the discussion